In our LiveTalk series, Being Patient spoke with husband and wife Mark and Brenda Roberts about their journey following Mark’s diagnosis of early-onset vascular…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…
One of Alzheimer’s disease’s key players, beta-amyloid presents a complex picture. If you or a loved one is going through the diagnostic process for…
Here’s a theory: Alzheimer’s biomarker beta-amyloid could — rather than killing the brain — actually be trying to defend it. The provocative idea builds on…
Johns Hopkins neuroscientist Mark Mattson, PhD, shares his insights on what we know so far — and the questions still to be answered —…
COVID-19 and Alzheimer’s share the same brain damage biomarkers. Blood samples reveal they accumulate at higher levels over a shorter period of time in…
The SYNTap Test, a new biomarker test to help diagnose diseases like Parkinson’s, Lewy body dementia and Multiple System Atrophy, is now on the…